187 related articles for article (PubMed ID: 16282417)
1. Orphan drugs and the NHS: consider whom drug regulation is designed to protect.
Marshall T
BMJ; 2005 Nov; 331(7525):1144. PubMed ID: 16282417
[No Abstract] [Full Text] [Related]
2. Orphan drugs and the NHS: should we value rarity?
McCabe C; Claxton K; Tsuchiya A
BMJ; 2005 Oct; 331(7523):1016-9. PubMed ID: 16254305
[TBL] [Abstract][Full Text] [Related]
3. Orphan drugs and the NHS: fairness in health care entails more than cost effectiveness.
Sheehan M
BMJ; 2005 Nov; 331(7525):1144-5. PubMed ID: 16282416
[No Abstract] [Full Text] [Related]
4. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum.
Simoens S; Picavet E; Dooms M; Cassiman D; Morel T
Appl Health Econ Health Policy; 2013 Feb; 11(1):1-3. PubMed ID: 23329382
[No Abstract] [Full Text] [Related]
6. [Orphan drugs: towards an economic evaluation].
Holué C
Rev Prat; 2012 Jan; 62(1):91-4. PubMed ID: 22335077
[No Abstract] [Full Text] [Related]
7. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
8. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
9. Orphan drugs revisited.
McCabe C; Tsuchiya A; Claxton K; Raftery J
QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
[No Abstract] [Full Text] [Related]
10. [Drugs for rare diseases].
Rolfs M; Lindemalm S
Lakartidningen; 2010 Apr 21-27; 107(16):1043. PubMed ID: 20476696
[No Abstract] [Full Text] [Related]
11. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
12. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
13. How can the risk that orphan drugs present to budgets be managed better?
O'Neill C
Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
[No Abstract] [Full Text] [Related]
14. EU to review rare disease drugs market exclusivity.
Sheridan C
Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455
[No Abstract] [Full Text] [Related]
15. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
16. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
17. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
18. Issues surrounding orphan disease and orphan drug policies in Europe.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Appl Health Econ Health Policy; 2010; 8(5):343-50. PubMed ID: 20804226
[TBL] [Abstract][Full Text] [Related]
19. Management of rare diseases.
Walshe JM
QJM; 2006 Feb; 99(2):123-4. PubMed ID: 16428334
[No Abstract] [Full Text] [Related]
20. Quantifying emerging drugs for very rare conditions.
Miles KA; Packer C; Stevens A
QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
